Anti-PHG-tau antibodies and their uses
The present invention relates to anti-PHF-tau antibodies and methods of making and using them.
1. A method of reducing paired helical filament tau (PHF-tau) accumulation in a patient comprising administering to a patient in need thereof a therapeutically effective amount of an isolated antibody or fragment thereof that binds paired helical filament tau (PHF-tau) comprising a heavy chain complementarity determining region (HCDR) 1, a heavy chain complementarity determining region (HCDR) 2 and a heavy chain complementarity determining region (HCDR) 3 of a heavy chain variable region (VH) of SEQ ID NO: 37, and a light chain complementarity determining region (LCDR) 1, a light chain complementarity determining region (LCDR) 2 and a light chain complementarity determining region (LCDR) 3 of a light chain variable region (VL) of SEQ ID NO: 38.
2. The method of claim 1 wherein, wherein the HCDR1, the HCDR2and the HCDR3 comprise amino acid sequences of SEQ ID NOs:13, 14 and 15, respectively, and the LCDR1, the LCDR2 and the LCDR3 comprise amino acid sequences of SEQ ID NOs: 16, 17 and 18, respectively.
3. The method of claim 2 wherein, wherein the HCDR1, the HCDR2and the HCDR3 consist of amino acid sequences of SEQ ID NOs:13, 14 and 15, respectively, and the LCDR1, the LCDR2 and the LCDR3 consists of amino acid sequences of SEQ ID NOs: 16, 17 and 18, respectively.
4. The method of claim 1 , wherein the HCDR1, the HCDR2 and the HCDR3 comprise amino acid sequences of SEQ ID NOs:25, 26 and 27, respectively, and the LCDR1, the LCDR2 and the LCDR3 comprise amino acid sequences of SEQ ID NOs: 28, 29 and 30, respectively.
5. The method of claim 4 , wherein the HCDR1, the HCDR2 and the HCDR3 consist of amino acid sequences of SEQ ID NOs:25, 26 and 27, respectively, and the LCDR1, the LCDR2 and the LCDR3 consist of amino acid sequences of SEQ ID NOs: 28, 29 and 30, respectively.
6. The method of claim 1 , wherein the VH comprises SEQ ID NO:37and the VL comprises SEQ ID NO:38.
7. The method of claim 6 , wherein the antibody is humanized.
8. The method of claim 1 , wherein the patient is suffering from Alzheimer's Disease.